{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:09Z","timestamp":1792784889505,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG#23438"],"award-info":[{"award-number":["IG#23438"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["ISS-SGZ-04\/22"],"award-info":[{"award-number":["ISS-SGZ-04\/22"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Associazione Italiana Leucemie Linfomi e Mieloma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01284-y","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:13:38Z","timestamp":1746170018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7494-0154","authenticated-orcid":false,"given":"Giulia","family":"Giorgetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Maroto-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Soncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Becherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Benzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ravera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Traverso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2868-739X","authenticated-orcid":false,"given":"Francesco","family":"Ladisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rivoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Truffelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-3167","authenticated-orcid":false,"given":"Aimable","family":"Nahimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Cagnetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Guolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara R. M.","family":"Uras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Schavgoulidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fong Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5068-8884","authenticated-orcid":false,"given":"Alessio","family":"Nencioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santina","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Massimo","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1432-9742","authenticated-orcid":false,"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-0799","authenticated-orcid":false,"given":"Michele","family":"Cea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"1284_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01051-5","volume":"14","author":"AJ Robinette","year":"2024","unstructured":"Robinette AJ, Huric L, Dona K, Benson D, Cottini F. CD56 expression predicts response to daratumumab-based regimens. Blood Cancer J. 2024;14:62.","journal-title":"Blood Cancer J"},{"key":"1284_CR2","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-21-0828","volume":"20","author":"F Cottini","year":"2022","unstructured":"Cottini F, Rodriguez J, Hughes T, Sharma N, Guo L, Lozanski G, et al. Redefining CD56 as a biomarker and therapeutic target in multiple myeloma. Mol Cancer Res. 2022;20:1083\u201395.","journal-title":"Mol Cancer Res"},{"key":"1284_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero J, de Tute R, Paiva B, Perez JJ, B\u00f6ttcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytom B Clin Cytom. 2016;90:61\u201372.","journal-title":"Cytom B Clin Cytom"},{"key":"1284_CR4","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood-2023-189439","volume":"142","author":"G Giorgetti","year":"2023","unstructured":"Giorgetti G, Becherini P, Maroto-Martin E, Fenoglio D, Soncini D, Martinuzzi C, et al. Higher CD56 expression on multiple myeloma cells increases CD38 expression, reduces intracellular NAD+ levels, and enhances the efficacy of daratumumab-based treatment strategies. Blood. 2023;142:1951","journal-title":"Blood"},{"key":"1284_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1152\/physrev.00035.2007","volume":"88","author":"F Malavasi","year":"2008","unstructured":"Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88:841\u201386.","journal-title":"Physiol Rev"},{"key":"1284_CR6","doi-asserted-by":"crossref","unstructured":"Becherini P, Soncini D, Ravera S, Gelli E, Martinuzzi C, Giorgetti G, et al. CD38-induced metabolic dysfunction primes multiple myeloma cells for NAD+-lowering agents. antioxidants (Basel) 2023;12:494.","DOI":"10.3390\/antiox12020494"},{"key":"1284_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-018-0174-7","volume":"6","author":"N Thongon","year":"2018","unstructured":"Thongon N, Zucal C, D\u2019Agostino VG, Tebaldi T, Ravera S, Zamporlini F, et al. Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA. Cancer Metab. 2018;6:1.","journal-title":"Cancer Metab"},{"key":"1284_CR8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/bloodadvances.2024013425","volume":"9","author":"D Soncini","year":"2025","unstructured":"Soncini D, Becherini P, Ladisa F, Ravera S, Chedere A, Gelli E, et al. NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma. Blood Adv. 2025;9:1024\u201339.","journal-title":"Blood Adv"},{"key":"1284_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00695-5","volume":"12","author":"S Kumar","year":"2022","unstructured":"Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12:98.","journal-title":"Blood Cancer J"},{"key":"1284_CR10","doi-asserted-by":"crossref","unstructured":"Sobh A, Encinas E, Patel AM, Surapaneni G, Bonilla E, Kaestner CL, et al. NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome. Blood 2024;144:283\u201395.","DOI":"10.1182\/blood.2023022859"},{"key":"1284_CR11","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096\u2013107.","journal-title":"Lancet"},{"key":"1284_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/ejh.13835","volume":"109","author":"I Spicka","year":"2022","unstructured":"Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022;109:504\u201312.","journal-title":"Eur J Haematol"},{"key":"1284_CR13","doi-asserted-by":"publisher","first-page":"20332","DOI":"10.1002\/cam4.6619","volume":"12","author":"K Bisht","year":"2023","unstructured":"Bisht K, Fukao T, Chiron M, Richardson P, Atanackovic D, Chini E, et al. Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. Cancer Med. 2023;12:20332\u201352.","journal-title":"Cancer Med"},{"key":"1284_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.trecan.2019.11.005","volume":"6","author":"BE Kennedy","year":"2020","unstructured":"Kennedy BE, Sadek M, Elnenaei MO, Reiman A, Gujar SA. Targeting NAD+ synthesis to potentiate CD38-based immunotherapy of multiple myeloma. Trends Cancer. 2020;6:9\u201312.","journal-title":"Trends Cancer"},{"key":"1284_CR15","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","volume":"25","author":"L Moreno","year":"2019","unstructured":"Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25:3176\u201387.","journal-title":"Clin Cancer Res"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01284-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:13:42Z","timestamp":1746170022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01284-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1284"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01284-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}